In an emerging field of research, active pharmaceutical ingredients (APIs) in liquid state (ionic liquids or double salt ionic liquids) have been shown to overcome the various drawbacks of their solid state counterparts. Liquid state APIs were shown to add enhanced drug properties such as increased solubility or an increase in a drug‘s affinity to be applied transdermally. Ionic liquids (ILs) are low melting ionic salts comprised of a cation and an anion in a 1:1 molar ratio. ILs containing three or more types of ions in varying molar ratios are classified as double salt ionic liquids (DSILs). Varying the molar ratio of consitiuents in a task specific pharmaceutical DSILs will contribute to the variety of chemical and physical properties of DSILs.<br/>By applying the IL strategy to a hepatoprotective medication such as N-acetyl-L-cysteine (NALC) and hepatotoxic drugs such as quinidine/quinine hydrochloride, the new hepatoprotective drugs would curtail drug induced liver injury (DILI). Moreover, combining these drugs with a penetration enhancer precursor (sodium docusate) will allow one to synthesize the corresponding DSILs as hepatoprotective medication that can be delivered transdermal. The research presented here focuses on investigating the transdermal delivery of several new quinidine and quinine ILs and DSILs.

Transdermal delivery of hepatoprotective drugs in liquid state

ACS Spring Meeting 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.